Intelligent Bio Solutions Inc.

News & Media

News Updates

NEW YORK, May 23, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance

NEW YORK, May 17, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful

Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024. Cash and cash equivalents as of March 31, 2024, was $9.40 million. Commenced FDA 510(k) clinical

Traditional drug tests can be intrusive, undignified, and uncomfortable for both test takers and administrators. The Intelligent Fingerprinting Drug Screening System detects commonly abused drugs via fingertip sweat analysis, eliminating the need for invasive and unpleasant urine, saliva, or blood collection.

Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition

Non-invasive health diagnostics are on the rise, and fingerprint testing technology is at the forefront. This article explores the history and ongoing development of fingerprint sweat analysis and its potential

NEW YORK, April 11, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening

NEW YORK, February 28, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership

NEW YORK, February 16, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on

Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023. Expanded into New Zealand market and increased market share in existing regions.

Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended December 31, 2023 NEW YORK, February 02, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS”

Customers identify in-house control, project flexibility, productivity, and cost reductions as key business benefits of fingerprint drug testing

Media

Seeking Alpha
News Medical Life Sciences
Nasdaq Logo
HIT Consultant
TMF+
LabMedica
GenomeWeb
mobi health news
WT wearable technologies
Medgadget
ECN
BioSpectrum
360 dx
DiagnosticsWorld
Biospace

Media Contact

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.

Request a Fingerprint Drug Test Demonstration

Non-invasive, cost-effective, and efficient workplace drug testing

Learn how our Intelligent Fingerprinting Drug Test can work for your business.

Book a no-obligation online or in-person demonstration today.